Skip to main content

Table 2a Characteristics of the included studies (n = 21)

From: Adherence to breast cancer guidelines is associated with better survival outcomes: a systematic review and meta-analysis of observational studies in EU countries

Study characteristics

n (%)

References

Country

 France

2 (10%)

[38, 39]

 Germany

15 (71%)

[18,19,20,21,22, 30, 37, 41,42,43, 45,46,47,48,49]

 Italy

2 (10%)

[17, 40]

 Netherlands

2 (10%)

[36, 44]

Publication year

 2015–2019

8 (35%)

[17,18,19,20,21,22, 45, 49]

 2009–2014

11 (52%)

[30, 40,41,42,43,44] [37, 39, 46,47,48]

  ≤ 2008

2 (10%)

[36, 38]

Study design

 Non-controlled before-after study

3 (14%)

[21, 38, 40]

 Retrospective cohort study

18 (86%)

[17,18,19,20, 22, 30, 36, 37, 39, 41,42,43,44,45,46,47,48,49]

Guideline scope

 Diagnosis

2 (10%)

[17, 40]

 Follow-up

1 (5%)

[38]

 Treatment

20 (95%)

[17,18,19,20,21,22, 30, 36, 37, 39,40,41,42,43,44,45,46,47,48,49]

Outcomes‡

 Overall survival

18 (86%)

[12,13,14,15,16,17, 24,25,26,27, 29, 31,32,33,34,35,36,37, 49]

 Disease free survival

16 (76%)

[13,14,15, 17, 24, 26, 28, 29, 31,32,33,34,35,36,37, 49]

 Costs associated to CGs adherence

2 (10%)

[38, 39]

 Quality of life

0 (0%)

 Incidence-based mortality

0 (0%)

 Harm

0 (0%)

Risk of bias

 Low

17 (81%)

[17, 20,21,22, 36, 37, 39,40,41,42,43,44, 46,47,48,49]

 Moderate

4 (20%)

[18, 19, 38, 45]

 High

0 (0%)

  1. ‡ Percentages exceed 100% because the categories are not mutually exclusive (i.e. some studies involved more than one type of guideline and more than one type of outcome)